.png){kind=icon}
.png){kind=icon}
Return
Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients
.png){kind=icon}
OA
AI
T
E
R
O
N
A
M
J
E
D
DOI：10.1111/all.70448.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Immune-related cutaneous adverse events (ircAEs) complicate management in many cancer patients receiving checkpoint inhibitor (CPI) immunotherapy. A new approach to early prognosis and ircAE treatment monitoring is needed in order to improve patient adherence to CPI immunotherapy.
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
A
IF:
12
Papers:
9.3K
Citations:
2.6W
Organization
Cited Papers